CytoMed Therapeutics (GDTC) Receivables - Net (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Receivables - Net for 5 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 8465.5% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 8465.5% year-over-year, with the annual reading at $1.2 million for FY2025, 61.63% up from the prior year.
  • Receivables - Net hit $1.2 million in Q4 2025 for CytoMed Therapeutics, up from $14119.9 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $1.2 million in Q4 2025 to a low of $14119.9 in Q4 2024.
  • Historically, Receivables - Net has averaged $531766.3 across 5 years, with a median of $566649.2 in 2021.
  • Biggest five-year swings in Receivables - Net: crashed 98.27% in 2024 and later skyrocketed 8465.5% in 2025.
  • Year by year, Receivables - Net stood at $566649.2 in 2021, then plummeted by 90.7% to $52704.8 in 2022, then skyrocketed by 1448.09% to $815920.1 in 2023, then plummeted by 98.27% to $14119.9 in 2024, then surged by 8465.5% to $1.2 million in 2025.
  • Business Quant data shows Receivables - Net for GDTC at $1.2 million in Q4 2025, $14119.9 in Q4 2024, and $815920.1 in Q4 2023.